CN108467396B - 一种更昔洛韦的制备方法 - Google Patents
一种更昔洛韦的制备方法 Download PDFInfo
- Publication number
- CN108467396B CN108467396B CN201810381321.9A CN201810381321A CN108467396B CN 108467396 B CN108467396 B CN 108467396B CN 201810381321 A CN201810381321 A CN 201810381321A CN 108467396 B CN108467396 B CN 108467396B
- Authority
- CN
- China
- Prior art keywords
- ganciclovir
- cooling
- heating
- hour
- crude product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 229960002963 ganciclovir Drugs 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 39
- PEZKHGVZZSQDPY-UHFFFAOYSA-N [2-[(2-acetamido-6-oxo-3h-purin-9-yl)methoxy]-3-acetyloxypropyl] acetate Chemical compound O=C1NC(NC(=O)C)=NC2=C1N=CN2COC(COC(C)=O)COC(C)=O PEZKHGVZZSQDPY-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000012043 crude product Substances 0.000 claims abstract description 29
- GILZZWCROUGLIS-UHFFFAOYSA-N n-(9-acetyl-6-oxo-3h-purin-2-yl)acetamide Chemical compound N1C(NC(=O)C)=NC(=O)C2=C1N(C(C)=O)C=N2 GILZZWCROUGLIS-UHFFFAOYSA-N 0.000 claims abstract description 15
- DUOPMEBLLUYTNT-UHFFFAOYSA-N [3-acetyloxy-2-(acetyloxymethoxy)propyl] acetate Chemical compound CC(=O)OCOC(COC(C)=O)COC(C)=O DUOPMEBLLUYTNT-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000001816 cooling Methods 0.000 claims description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- 238000010438 heat treatment Methods 0.000 claims description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 238000001914 filtration Methods 0.000 claims description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 26
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 17
- 238000010992 reflux Methods 0.000 claims description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 238000002425 crystallisation Methods 0.000 claims description 11
- 230000008025 crystallization Effects 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 230000007935 neutral effect Effects 0.000 claims description 9
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 8
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000002386 leaching Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 6
- 229910015900 BF3 Inorganic materials 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- CHNLPLHJUPMEOI-UHFFFAOYSA-N oxolane;trifluoroborane Chemical compound FB(F)F.C1CCOC1 CHNLPLHJUPMEOI-UHFFFAOYSA-N 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims 3
- 238000010025 steaming Methods 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 8
- 239000003054 catalyst Substances 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- QNXFUWFRTWSSOK-UHFFFAOYSA-N n-acetyl-n-(6-oxo-3,7-dihydropurin-2-yl)acetamide Chemical compound O=C1NC(N(C(C)=O)C(=O)C)=NC2=C1NC=N2 QNXFUWFRTWSSOK-UHFFFAOYSA-N 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 description 15
- -1 halomethyl ethers Chemical class 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 230000005494 condensation Effects 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 238000006264 debenzylation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- YSKNLNWQGKWXNA-UHFFFAOYSA-N (2,3-diacetyloxy-3-methoxypropyl) acetate Chemical compound CC(=O)OC(OC)C(OC(C)=O)COC(C)=O YSKNLNWQGKWXNA-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- GDBPXOZUOLBXAR-UHFFFAOYSA-N [2-(chloromethoxy)-3-phenylmethoxypropoxy]methylbenzene Chemical compound C=1C=CC=CC=1COCC(OCCl)COCC1=CC=CC=C1 GDBPXOZUOLBXAR-UHFFFAOYSA-N 0.000 description 1
- FCOKLAMVAHWFCI-UHFFFAOYSA-N acetyloxymethoxymethyl acetate Chemical class CC(=O)OCOCOC(C)=O FCOKLAMVAHWFCI-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- FQGYCXFLEQVDJQ-UHFFFAOYSA-N mercury dicyanide Chemical compound N#C[Hg]C#N FQGYCXFLEQVDJQ-UHFFFAOYSA-N 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- MXSMRDDXWJSGMC-UHFFFAOYSA-N n-(6-oxo-3,7-dihydropurin-2-yl)acetamide Chemical compound N1C(NC(=O)C)=NC(=O)C2=C1N=CN2 MXSMRDDXWJSGMC-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- HNYIJJOTPSKGJM-UHFFFAOYSA-N propoxymethyl acetate Chemical compound CCCOCOC(C)=O HNYIJJOTPSKGJM-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000002444 silanisation Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
Abstract
Description
碱 | 收率 | 纯度 |
10%Na<sub>2</sub>CO<sub>3</sub> | 64.7% | 90.5% |
10%K<sub>2</sub>CO<sub>3</sub> | 68.6% | 91.8% |
10%CS<sub>2</sub>CO<sub>3</sub> | 68.2% | 92.0% |
10%NaHCO<sub>3</sub> | 0 | N/A |
10%KOH | 84.2% | 97.1% |
10%NaOH | 76.9% | 94.3% |
20%KOH | 75.4% | 92.4% |
20%NaOH | 70.2% | 93.7% |
5%KOH | 83.3% | 96.8% |
5%NaOH | 75.5% | 93.2% |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810381321.9A CN108467396B (zh) | 2018-04-25 | 2018-04-25 | 一种更昔洛韦的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810381321.9A CN108467396B (zh) | 2018-04-25 | 2018-04-25 | 一种更昔洛韦的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108467396A CN108467396A (zh) | 2018-08-31 |
CN108467396B true CN108467396B (zh) | 2021-07-20 |
Family
ID=63263765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810381321.9A Active CN108467396B (zh) | 2018-04-25 | 2018-04-25 | 一种更昔洛韦的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108467396B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110585141A (zh) * | 2019-09-19 | 2019-12-20 | 湖北科益药业股份有限公司 | 一种稳定的更昔洛韦冻干粉针剂 |
CN111087397A (zh) * | 2019-12-31 | 2020-05-01 | 湖北葛店人福药业有限责任公司 | 一种单乙酰更昔洛韦母液回收利用方法 |
CN113149988B (zh) * | 2021-04-23 | 2023-04-28 | 海南锦瑞制药有限公司 | 更昔洛韦的制备方法及应用 |
CN113354647A (zh) * | 2021-06-30 | 2021-09-07 | 海南海灵化学制药有限公司 | 一种更昔洛韦钠的合成工艺 |
CN115504977B (zh) * | 2022-09-23 | 2024-02-09 | 海南锦瑞制药有限公司 | 更昔洛韦的制备方法及注射用更昔洛韦的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100999507A (zh) * | 2006-12-28 | 2007-07-18 | 樊福定 | 工业化制备烯丙基缩水甘油醚的方法 |
CN101402721A (zh) * | 2008-11-04 | 2009-04-08 | 三门峡市峡威化工有限公司 | 一种聚合型受阻酚防老剂616的制备方法 |
CN102492149B (zh) * | 2011-11-24 | 2013-03-20 | 中国海洋石油总公司 | 一种非离子型水性环氧树脂固化剂的制备方法 |
CN102702199A (zh) * | 2012-06-13 | 2012-10-03 | 湖北葛店人福药业有限责任公司 | 一种制备更昔洛韦的方法 |
-
2018
- 2018-04-25 CN CN201810381321.9A patent/CN108467396B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN108467396A (zh) | 2018-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108467396B (zh) | 一种更昔洛韦的制备方法 | |
CN111440170B (zh) | 一种利用鸟苷合成鸟嘌呤的方法 | |
CN106256824B (zh) | 一种高纯度德拉沙星葡甲胺盐的制备方法 | |
CN112321395B (zh) | 金属化物/钯化合物催化还原体系在烯丙氧基萘脱烯丙基反应中的应用 | |
CN111808034B (zh) | 一种合成1,2,4-三氮唑-3-羧酸甲酯的方法 | |
CN114524795B (zh) | 一种改进的Rhodomyrtone制备方法 | |
CN112300071B (zh) | 一种高纯度磷酸氯喹的合成方法 | |
CN108014113B (zh) | 丁酰氨基二甲氧基苯并[d]氮杂*基喹唑啉类化合物在制备治疗宫颈癌药物中的应用 | |
CN103373963B (zh) | 盐酸帕唑帕尼的中间体及其制备方法 | |
CN111072656B (zh) | 一种吡喹酮的合成方法 | |
CN108117542B (zh) | 丙酰氨基甲氧苯基苯并[d]氮杂卓基喹唑啉类化合物及制备和应用 | |
CN108329299B (zh) | 丁酰氨基氯代苯并[d]氮杂*基喹唑啉类化合物及制备和应用 | |
JPS5855485A (ja) | グアニンの精製法 | |
CN110862394A (zh) | 一种pde9a抑制剂的制备方法 | |
CN110746367B (zh) | 一种1,2,4-三氮唑-3-羧酸甲酯的合成方法 | |
CN103524585A (zh) | 一种应用离子液体制备玉米素类化合物的方法 | |
CN108863917A (zh) | 一种2,5-二甲氧基吡啶的制备方法 | |
CN114394908B (zh) | 一种制备2-羟基-3-氨基苯乙酮的方法 | |
CN108014116B (zh) | 氨基二甲氧基苯并[d]氮杂*基喹唑啉类化合物在制备治疗肺癌药物中的应用 | |
CN108752339B (zh) | 一种喹叨啉及其衍生物的合成方法 | |
CN108143736B (zh) | 丁酰氨基苯并[d]氮杂*基喹唑啉类在制备治疗肺癌药物中的应用 | |
CN108014115B (zh) | 特戊酰氨基甲氧苯基苯并[d]氮杂*基喹唑啉类化合物在制备治疗肺癌药物中的应用 | |
CN116514723A (zh) | 一种5,6-2氯-1-乙基-1h-苯并咪唑-2酮(dcebio)的合成方法 | |
EP2417118B1 (en) | A process for manufacturing zeranol | |
CN106397312B (zh) | 一种制备glyt-1抑制剂的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of ganciclovir Effective date of registration: 20221019 Granted publication date: 20210720 Pledgee: Xingye Bank Limited by Share Ltd. Anqing branch Pledgor: ANHUI HAIKANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980018855 |
|
CP03 | Change of name, title or address |
Address after: 246000 No.21, Huancheng West Road, Daguan District, Anqing City, Anhui Province Patentee after: Anhui Haikang Pharmaceutical Co.,Ltd. Country or region after: China Address before: 246000 No.21, Huancheng West Road, Daguan District, Anqing City, Anhui Province Patentee before: ANHUI HAIKANG PHARMACEUTICAL Co.,Ltd. Country or region before: China |